N/A
N=13
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
Type 1 Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT00831389 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcome: Primary: Plasma Glucose (PG) Response to Exercise — 75; 90.5 mg/dL — p=0.791
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Closed Loop (Device)
- Age
- Pediatric, Adult · 12+ yrs
- Sex
- All
- Sponsor
- Medtronic MiniMed, Inc.
- Primary completion
- Nov 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Glucose (PG) Response to Exercise |
75; 90.5 | 0.791 |
| PRIMARY Incidence of Hypoglycemia Immediately Following Exercise |
0; 0 | 0.5 |
| PRIMARY Incidence of Nocturnal Hypoglycemia Following Exercise |
0; 0 | 0.25 |
| SECONDARY Peak Post-prandial Plasma Glucose (PG) |
188; 229.75 | 0.0669 |
| SECONDARY Nadir Plasma Glucose (PG) Immediately Following Exercise |
80.5; 70.5 | 0.2256 |
| SECONDARY Overnight Nadir Plasma Glucose (PG) |
74.5; 93.5 | 0.791 |
| SECONDARY Percentage of Time Plasma Glucose (PG) is Within the Euglycemic Range. |
74.1; 79.8 | 0.2036 |
| SECONDARY Percentage of Time Plasma Glucose (PG) is Above the Euglycemic Range. |
19.7; 17.3 | 0.6221 |
| SECONDARY Percentage of Time Plasma Glucose (PG) is Below the Euglycemic Range. |
6; 1.1 | 0.021 sig |
Summary
The purpose of the study is to compare the glycemic control during and following aerobic exercise using either an open or closed-loop insulin delivery system.
Eligibility Criteria
Inclusion Criteria
- Male and female subjects between 12-30 years of age.
- Subjects must weigh at least 50 kg to accommodate phlebotomy.
- Previously diagnosed Type 1 Diabetes Mellitus
- Diabetes duration at least 1 year.
- Currently treating their diabetes with an insulin pump.
- A1C of ≤ 9.0 % at time of enrollment.
- Willing to have an intravenous (IV) line inserted for frequent blood sampling and infusion of glucose if needed.
- Willing to wear two (2) subcutaneous glucose sensors and two (2) transmitters simultaneously during closed-loop portion of the study.
- Be in good general health without other acute or chronic illnesses except treated hypothyroidism or celiac disease and asthma not requiring glucocorticoid use.
- Able to tolerate a 75-minute exercise period of moderate intensity.
- Speak and understand English.
- Subject and parent (if minor) must be able to comprehend and sign the informed consent form and other study documents.
Exclusion Criteria
- Pregnancy (urine pregnancy test) or lactation, if female.
- Subject has any major concomitant disease or any physical or psychological disorder within the last five years, which might be considered life threatening, or which might confound the collection or interpretation of the study data.
- Subject has a cardiac pacemaker or similar device that may be sensitive to radio frequency telemetry.
- Subject using any of the following medications:
- glucocorticoids
- cyclosporine
- L-asparaginase
- niacin
- protease inhibitors
- anti-psychotics
- GnRH agonists
- beta-blockers
- calcium channel blockers
- immunosuppressants
- over-the-counter medications that may effect glucose metabolism.
- Subject has any of the following conditions
- insulin allergy
- severe insulin resistance
- exercise-induced asthma
- musculoskeletal problems that may impact ability to complete exercise protocol
- substance abuse
- skin ulcers or poor wound healing
- bleeding disorders
- chronic infections
- eating disorders
- give a history of or are predisposed to major stress
- any other major organ system disease.
- Subject has experienced two (2) or more severe hypoglycemic events -seizures/coma requiring assistance in the past six (6) months.
- Subject has any other condition that in the investigator's opinion warrants exclusion from the study or precludes him/her from completing the protocol.
- Subjects using dietary supplements within 14 days of study enrollment
- Subject is currently enrolled in another study.
Data sourced from ClinicalTrials.gov (NCT00831389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.